N海光上市暴漲翻倍 大股東中科曙光盤中一度逼近跌停
格隆匯8月12日丨科創板新股N海光(688041.SH)今日上市暴漲,股價一度翻倍,市值一度超1700億元;但其第一大股東中科曙光盤中卻一度逼近跌停,不過在前兩週該股已累漲超22%。據悉,海光信息長期致力於高端處理器的設計與研發,並攻克了高端處理器設計的若干核心技術,形成了大量的自主知識產權,是國內少數同時具備高端通用處理器和協處理器研發能力的集成電路設計企業,也有人稱之為“高端CPU第一股”。海光信息上市公吿書顯示,中科曙光持股6.5億股,在本次IPO發行前,中科曙光持股佔比32.1%,在發行後持股佔比27.96%。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.